|
|
Adaptimmune Therapeutics Plc (NASDAQ: ADAP) |
|
Price: $0.6300
$0.01 
1.140%
|
| Day's High:
| $0.65
| Week Perf:
| -10 %
|
| Day's Low: |
$ 0.61 |
30 Day Perf: |
-23.87 % |
| Volume (M): |
1,268 |
52 Wk High: |
$ 2.05 |
| Volume (M$): |
$ 799 |
52 Wk Avg: |
$1.04 |
| Open: |
$0.62 |
52 Wk Low: |
$0.43 |
|
|
| Market Capitalization (Millions $) |
967 |
| Shares
Outstanding (Millions) |
1,535 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
181 |
| Net Income (TTM) (Millions $) |
-45 |
| Cash Flow (TTM) (Millions $) |
26 |
| Capital Exp. (TTM) (Millions $) |
2 |
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc is a biopharmaceutical company that specializes in the development of novel, personalized immunotherapies for the treatment of cancer. The company utilizes its T-cell receptor (TCR) platform to engineer T-cells to recognize and target specific cancer cells.
Adaptimmune's approach involves modifying a patient's own T-cells to express a specific TCR that can recognize cancer cells expressing a specific antigen. This personalized immunotherapy approach aims to enhance the body's immune response against cancer while minimizing damage to healthy cells.
The company has multiple clinical-stage programs targeting various types of solid tumors and hematologic malignancies. Their lead product candidate, ADP-A2M4, is currently being evaluated in Phase 2 trials for the treatment of multiple solid tumor types, including synovial sarcoma and head and neck cancer.
Adaptimmune also collaborates with pharmaceutical companies, including GlaxoSmithKline and Astellas Pharma, to further develop and commercialize its immunotherapy technologies. Overall, Adaptimmune Therapeutics Plc is focused on advancing the field of personalized cancer immunotherapy to provide more effective and durable treatments for patients.
Company Address: 60 Jubilee Avenue, Milton Park Abingdon, Oxfordshire 0
Company Phone Number: 1235 430000 Stock Exchange / Ticker: NASDAQ ADAP
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Aug 2 2024 12:47 AM UTC
FDA Grants Accelerated Approval for TECELRA: Pioneering Engineered Cell Therapy for Solid Tumors CSIMarket.com Staff Writer Adaptimmune Therapeutics plc, a biopharmaceutical company focused on developing cell therapies for cancer treatment, has received accelerated approval from the U.S. Food and Drug Administration (FDA) for TECELRA (afamitresgene autoleucel). This landm...
|
| Adaptimmune Therapeutics Plc
The recent financial results of Adaptimmune Therapeutics Plc have sent shockwaves through the market, revealing a disastrous start to the year. The company disclosed its January to March 31, 2024 numbers, and the figures are far from encouraging.
During this period, Adaptimmune experienced a staggering decline in revenue, which plummeted by a significant -85.453%, falling to a meager $7.02 million. This drastic reduction has raised numerous concerns among investors, as it represents a dramatic departure from the prior reporting season. In the same period a year before, the company recorded revenue doubling sequentially by an astonishing 284.401% from $1.83 million. This stark contrast illustrates the severe setbacks faced by the company in recent times.
|
| Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc, a leading biotechnology and pharmaceutical company, recently released its financial results for the October to December 31 2023 fiscal span. The company has experienced challenges with decreasing revenue, widening net deficit, and below-average accounts receivable values. Although there have been some positive developments, Adaptimmune Therapeutics Plc continues to face an uphill battle in recovering its financial stability.
Revenue Decline and Continual Losses
During the specified fiscal span, Adaptimmune Therapeutics Plc reported a substantial decline in revenue. The revenue dwindled by an alarming -84.183% to $1.83 million, compared to $11.55 million in the same period a year ago. Even when compared sequentially, the revenue tumbled by -80.703% from $9.47 million.
The company's financial performance exhibited a persistent trend of losses, registering a deficit of $-0.03 per share, similar to the previous year. This trend continued throughout the fiscal period, with Adaptimmune Therapeutics Plc reporting a net deficit of $-47.917 million, significantly higher than the $-29.250 million recorded a year ago.
|
| Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc has witnessed a subtle increase of 0.9% in its stock during the last five trading days. However, the year-to-date performance remains concerning, with a significant decline of -66.47%. Let's delve deeper into the recent financial results and evaluate how they might impact the company's future prospects.
Revenue Growth Amidst Industry Challenges:
In the most recent fiscal period, Adaptimmune Therapeutics Plc reported an impressive surge in revenue of 29.15% to $9.47 million compared to the same quarter of the previous year. This revenue increase is particularly remarkable when compared to the top-line reduction experienced by most of its peers in the Biotechnology & Pharmaceuticals sector during the matching period.
While the revenue growth is encouraging, it is essential to acknowledge that the company has still incurred a loss of $-0.03 per share. However, this loss reflects an improvement from the previous quarter, in which the loss per share was $-0.02.
|
| Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc, a biotechnology company specializing in cell-based immunotherapies, recently reported its financial results for the period ending June 30, 2023. While the company's revenue showed a promising increase of 13.198% compared to the same period last year, reaching $6.67 million, it still experienced a loss of $0.02 per share.
This loss is a significant improvement from the prior financial reporting period, where Adaptimmune's revenue tumbled by -86.178% to $48.28 million, resulting in a zero earnings per share. In terms of net shortfall, the company reported a loss of $21.389 million in the current period, compared to a deficit of $44.520 million in the previous year's comparable period.
One positive aspect worth noting is the increase in accounts receivable, which indicates rising demand for Adaptimmune's products. The accounts receivables were valued at $3.0 million, representing an increase from the preceding quarter. This demonstrates the company's ability to attract customers and generate future revenue.
Looking ahead, Adaptimmune Therapeutics Plc is expected to release its next financial results on November 7, 2023. Investors and analysts will closely observe these results to assess the company's progress and potential for growth.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.03 $ |
| Revenues (TTM) |
0.12 $
|
| Cash Flow (TTM) |
0.02 $ |
| Cash |
0.12 $
|
| Book Value |
0.05 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.03 $
|
| Revenues (TTM) |
0.12 $ |
| Cash Flow (TTM) |
0.02 $ |
| Cash |
0.12 $
|
| Book Value |
0.05 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.36% 